MRG reports that CMS’s inclusion of home sleep testing in its 2009 Physician Fee Schedule is the largest reason for the increased market value.
"This change is expected to significantly expand the [number] of people getting tested for OSA and receiving treatment," says Ravindra Sharma, senior analyst at MRG. "Additionally, this change in reimbursement will also result in significant savings for CMS, because home sleep tests cost a fraction of in-lab polysomnographies. As a result, demand for therapeutic OSA devices will be very high through 2014."
“US Market Opportunities for Respiratory and Sleep Management Devices 2010” provides insight into emerging trends for therapeutic OSA devices, ventilators, oxygen therapy, and sleep diagnostic systems through 2014.